Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Franco Locatelli, Michael B. Jordan, MD, Carl E. Allen, MDPhD, Simone Cesaro, MD, Carmelo Rizzari, MD, Anupama Rao, MD, Barbara Degar, MD, Timothy Garrington, Julian Sevilla, MD PhD, Maria Caterina Putti, MD, Franca Fagioli, MD, Martina Ahlmann, MD, Jose-Luis Dapena, MD, Alexei A. Grom, MD, Fabrizio De Benedetti, MD, Walter Giovanni Ferlin, PhD, Maria Ballabio, MD, Cristina De Min, MD

Blood (2018) 132 (Supplement 1): LBA-6.

https://doi.org/10.1182/blood-2018-120810

Published: 2018

Journal Articles

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

Erica Dander, PhD, Federica Portale, PhD, Daniela Silvestri, Giulia Cricrì, Silvia Bresolin, PhD, Stefania Gaspari, Barbara Russo, Monica Lupi, Paolo Ubezio, Geertruy te Kronnie, Maria Grazia Valsecchi, PhD, Franco Locatelli, Carmelo Rizzari, MD, Andrea Biondi, MD, Giovanna D'Amico, BSc, PhD MSc

Blood (2018) 132 (Supplement 1): 1296.

https://doi.org/10.1182/blood-2018-99-116668

Published: 2018

Journal Articles

The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study

Blood (2016) 128 (22): 2896.

https://doi.org/10.1182/blood.V128.22.2896.2896

Published: 2016

Journal Articles

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

C. Michel Zwaan, MD PhD, Stefan Söderhäll, MD PhD, Benoit Brethon, MD, Matteo Luciani, MD, Carmelo Rizzari, MD, David Sternberg, MD PhD, Emmanuelle Besse, Catherine Dutreix, MD, Franca Fagioli, MD, Phoenix Ho, MD, Carlo Dufour, MD, Rob Pieters, MD PhD

Blood (2015) 126 (23): 2564.

https://doi.org/10.1182/blood.V126.23.2564.2564

Published: 2015

Journal Articles

Genetic Characterization Of Williams Beuren Syndrome Associated With Non-Hodgkin Lymphoma

David Guenat, Carmelo Rizzari, MD, PhD, Patrick Edery, MD, PhD, Jean Soulier, MD, PhD, Christophe Ferrand, PhD, Christophe Borg, MD, PhD, Pierre-Simon Rohrlich, MD, PhD

Blood (2013) 122 (21): 4898.

https://doi.org/10.1182/blood.V122.21.4898.4898

Published: 2013

Journal Articles

Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome

Martina Pigazzi, Ph.D., Valzerda Beqiri, MD, Elena Manara, PhD, Roberto Rondelli, Riccardo Masetti, MD, Carmelo Rizzari, MD, PhD, Maria Caterina Putti, Andrea Pession, Franco Locatelli, Giuseppe Basso, MD

Blood (2013) 122 (21): 3884.

https://doi.org/10.1182/blood.V122.21.3884.3884

Published: 2013

Journal Articles

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Costa Bachas, MSc, Gerrit Jan Schuurhuis, PhD, Dirk Reinhardt, MD, Ursula Creutzig, MD, PhD, Zinia J. Kwidama, BSc, C. Michel Zwaan, MD, PhD, Marry M. van den Heuvel-Eibrink, Evelina S De Bont, MD, PhD, Sara Elitzur, MD, Carmelo Rizzari, MD, PhD, Valérie de Haas, MD, PhD, Martin Zimmermann, Jacqueline Cloos, PhD, Gertjan J.L. Kaspers, MD, PhD

Blood (2012) 120 (21): 2480.

https://doi.org/10.1182/blood.V120.21.2480.2480

Published: 2012

Journal Articles

Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol

Riccardo Masetti, MD, Martina Pigazzi, PhD, Andrea Pession, Prof, MD, Carmelo Rizzari, MD, PhD, Nicola Santoro, Luca lo Nigro, Matteo Luciani, Giuseppe Menna, Roberto Rondelli, Giuseppe Basso, Franco Locatelli

Blood (2012) 120 (21): 3585.

https://doi.org/10.1182/blood.V120.21.3585.3585

Published: 2012

Journal Articles

Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol

Franco Locatelli, Maria Caterina Putti, Andrea Pession, Prof, MD, Franca Fagioli, MD, Giuseppe Menna, Concetta Micalizzi, Carmelo Rizzari, MD, PhD, Sergio Rutella, MD PhD, Andrea Biondi, MD, Barbara Buldini, Riccardo Masetti, MD, Giuseppe Basso

Blood (2012) 120 (21): 3586.

https://doi.org/10.1182/blood.V120.21.3586.3586

Published: 2012

Journal Articles

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Adriana Balduzzi, MD, Maria Grazia Valsecchi, PhD, André Schrauder, MD, Daniela Silvestri, MSc, Barbara Buldini, MD, Arend von Stackelberg, MD, Anna Maria Testi, MD, Thomas Klingebiel, MD, Christina Peters, MD, Carmelo Rizzari, MD, Elena Barisone, MD, Martin Schrappe, MD

Blood (2008) 112 (11): 915.

https://doi.org/10.1182/blood.V112.11.915.915

Published: 2008

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

NARROW

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

Activin A, a Potential Key Factor of the Malignant Bone Marrow Niche, Enhances B-Cell Precursor-Acute Lymphoblastic Leukemic Cell Migratory and Invasive Properties

The Prognostic Impact of Cytogenetics and Karyotype Changes in Pediatric Patients with Relapsed Acute Myeloid Leukemia: A Retrospective Cohort Study within the Relapsed AML 2001/01 Study

A Phase 1/2, Open-Label, Dose-Escalation Study of Midostaurin in Pediatric Patients (Pts) with Relapsed or Refractory (R/R) Acute Leukemia: Final Results of Study ITCC-024 (CPKC412A2114)

Genetic Characterization Of Williams Beuren Syndrome Associated With Non-Hodgkin Lymphoma

Core Binding Factor Acute Myeloid Leukemia In Pediatric Patients Enrolled In The AIEOP AML 2002/01 Trial: The Impact Of Minimal Residual Disease On Patient Outcome

Frequency and Prognostic Relevance of Gene Mutations in Pediatric AML Patients At First Relapse.

Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol

Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol

Relapse in Childhood “Very High Risk” Acute Lymphoblastic Leukemia Treated with BFM Chemotherapy Has a Dismal Outcome Even When Treated with Transplantation.

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only